INCR
Price
$1.34
Change
-$0.01 (-0.74%)
Updated
Nov 28 closing price
Capitalization
73.15M
152 days until earnings call
Intraday BUY SELL Signals
TLRY
Price
$0.81
Change
-$0.22 (-21.36%)
Updated
Nov 28 closing price
Capitalization
943.08M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INCR vs TLRY

Header iconINCR vs TLRY Comparison
Open Charts INCR vs TLRYBanner chart's image
Intercure
Price$1.34
Change-$0.01 (-0.74%)
Volume$2.32K
Capitalization73.15M
Tilray Brands
Price$0.81
Change-$0.22 (-21.36%)
Volume$98.56M
Capitalization943.08M
INCR vs TLRY Comparison Chart in %
INCR
Daily Signal:
Gain/Loss:
TLRY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
INCR vs. TLRY commentary
Nov 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 29, 2025
Stock price -- (INCR: $1.34 vs. TLRY: $0.81)
Brand notoriety: INCR: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: INCR: 3% vs. TLRY: 131%
Market capitalization -- INCR: $73.15M vs. TLRY: $943.08M
INCR [@Pharmaceuticals: Generic] is valued at $73.15M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $943.08M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCR’s FA Score shows that 1 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • INCR’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, both INCR and TLRY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCR’s TA Score shows that 2 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • INCR’s TA Score: 2 bullish, 3 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than INCR.

Price Growth

INCR (@Pharmaceuticals: Generic) experienced а +2.04% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -10.25% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.90%. For the same industry, the average monthly price growth was -2.36%, and the average quarterly price growth was +17.65%.

Reported Earning Dates

INCR is expected to report earnings on Apr 30, 2026.

TLRY is expected to report earnings on Jan 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.90% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($943M) has a higher market cap than INCR($73.1M). INCR YTD gains are higher at: -15.868 vs. TLRY (-38.872). INCR has higher annual earnings (EBITDA): -39.54M vs. TLRY (-2.11B). TLRY has more cash in the bank: 265M vs. INCR (20.3M). INCR has less debt than TLRY: INCR (151M) vs TLRY (324M). TLRY has higher revenues than INCR: TLRY (831M) vs INCR (273M).
INCRTLRYINCR / TLRY
Capitalization73.1M943M8%
EBITDA-39.54M-2.11B2%
Gain YTD-15.868-38.87241%
P/E Ratio25.48N/A-
Revenue273M831M33%
Total Cash20.3M265M8%
Total Debt151M324M47%
FUNDAMENTALS RATINGS
INCR vs TLRY: Fundamental Ratings
INCR
TLRY
OUTLOOK RATING
1..100
243
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9097
PRICE GROWTH RATING
1..100
7754
P/E GROWTH RATING
1..100
493
SEASONALITY SCORE
1..100
5047

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (50) in the Biotechnology industry is in the same range as INCR (58) in the Servicestothe Health Industry industry. This means that TLRY’s stock grew similarly to INCR’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that TLRY’s stock grew similarly to INCR’s over the last 12 months.

INCR's SMR Rating (90) in the Servicestothe Health Industry industry is in the same range as TLRY (97) in the Biotechnology industry. This means that INCR’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (54) in the Biotechnology industry is in the same range as INCR (77) in the Servicestothe Health Industry industry. This means that TLRY’s stock grew similarly to INCR’s over the last 12 months.

INCR's P/E Growth Rating (4) in the Servicestothe Health Industry industry is significantly better than the same rating for TLRY (93) in the Biotechnology industry. This means that INCR’s stock grew significantly faster than TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCRTLRY
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 12 days ago
81%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
INCR
Daily Signal:
Gain/Loss:
TLRY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTAAX12.84N/A
N/A
Fidelity Advisor Asset Manager 30% A
LCBOX31.99N/A
N/A
ClearBridge Dividend Strategy 1
WRAAX13.97N/A
N/A
Wilmington Global Alpha Equities A
EGORX20.93N/A
N/A
Allspring Large Cap Core R6
TSMDX16.03N/A
N/A
Trillium ESG Small/Mid Cap Institutional

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and CRON have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and CRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
-0.91%
CRON - INCR
26%
Poorly correlated
-0.40%
SNDL - INCR
25%
Poorly correlated
+1.15%
ACB - INCR
25%
Poorly correlated
+0.22%
TLRY - INCR
24%
Poorly correlated
-21.07%
DVAX - INCR
23%
Poorly correlated
-0.52%
More